CannAssure Therapeutics

Company Overview

Snapshot

Founded in January 2016 by Nir Peles, CannAssure Therapeutics operates with 1–10 employees. The company has raised $3.44 million across two funding rounds and was publicly listed on TASE in December 2018.

Business overview

CannAssure Therapeutics is a Health Tech & Life Sciences company focused on developing and commercializing medical cannabis products and pharmaceutical cannabinoid medicines. The company utilizes a holistic integrated production system, including an indoor aeroponic grow facility and an extraction and processing facility, supported by scientific research and development. Operating in accordance with IMC-GAP standards, CannAssure tests its cultivated cannabis and manufactured products at various stages to ensure purity, effectiveness, stability, and consistency. Its product portfolio includes Cannassure Drops and Cannassure Select Inflorescences, serving the medical cannabis and pharmaceutical markets.

Strategic signal

In February 2022, CannAssure Therapeutics secured an exclusive agreement for the cultivation, marketing, and sale of the Freud Super Ego cannabis strain, covering all products based on the strain or its flower. This strategic move, in collaboration with RCK, signals the company's commitment to expanding its product offerings and market share within the medical cannabis sector, enhancing its competitive position through proprietary strain access.

Company Intelligence Q&A

What was a significant product development for CannAssure Therapeutics?

In August 2021, CannAssure Therapeutics was granted a patent by the Israel Patents Authority for an oral delivery method of cannabis and cannabinoid compositions. This technology allows for precise dosing of active ingredients through oral ingestion, expanding access to cannabis-based treatments.

What strategic partnership did CannAssure Therapeutics form in late 2021?

In November 2021, CannAssure Therapeutics announced a partnership agreement with CiiTECH to produce and distribute Provacan brand cannabis oils in Israel. This collaboration aims to educate users on the effectiveness of CiiTECH's oils and expand the market for cannabis products in Israel.

What distribution agreement did CannAssure Therapeutics establish for Scandinavian markets?

In December 2020, CannAssure Therapeutics signed an exclusive distribution agreement with DanCann Pharma to distribute its medical cannabis products in Denmark, Norway, Sweden, and Finland. This agreement supports CannAssure's strategy of expanding its business and product pipeline in Europe.

When did CannAssure Therapeutics complete a feasibility study for topical medical cannabis products?

In September 2020, CannAssure Therapeutics successfully completed a feasibility study for the development of topical medical cannabis products for skin inflammation, in collaboration with Lipidor AB. This project, partially funded by the Israeli Innovation Authority, aims to combine cannabinoids with Lipidor's AKVANO® technology for localized administration.

What was a key international market entry for CannAssure Therapeutics?

In December 2020, CannAssure Therapeutics exported its Cannassure Drops to France for the first time as part of a pilot program for medical cannabis. The company also signed a memorandum of understanding with a French pharmaceutical company for collaboration in this pilot program, marking a significant step towards its European development.